Low Anterior Resection Syndrome: Predisposing Factors and Treatment.

Bowel dysfunction Low anterior resection syndrome Management Quality of life Rectal cancer Risk factors

Journal

Surgical oncology
ISSN: 1879-3320
Titre abrégé: Surg Oncol
Pays: Netherlands
ID NLM: 9208188

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 01 09 2021
accepted: 24 11 2021
pubmed: 6 12 2021
medline: 14 9 2022
entrez: 5 12 2021
Statut: ppublish

Résumé

Bowel dysfunction after restorative proctectomy, commonly referred to as Low Anterior Resection Syndrome (LARS), is a common long-term sequela of rectal cancer treatment that has a significant impact on a patient's quality of life. While the pathophysiology of LARS is poorly understood, its underlying cause that it is likely multifactorial, and there are numerous patient, tumor, and treatment-level factors associated with its development. In accordance with these risk factors, several strategies have been proposed to mitigate LARS postoperatively, including modifications in the technical approach to restorative proctectomy and advancements in the multidisciplinary care of rectal cancer. Furthermore, a clinically applicable pre-operative nomogram has been developed to estimate the risk of LARS postoperatively, which may help in counseling patients before surgery. The management of LARS begins with identifying those who manifest symptoms, as postoperative bowel dysfunction often goes unrecognized. This goal is best achieved with the systematic screening of patients using validated Patient-Reported Outcome Measures. Once a patient with LARS is identified, conservative management strategies should be implemented. When available, a dedicated LARS nurse and/or multidisciplinary team can be an invaluable resource in engaging patients and educating them regarding LARS self-care. If symptoms of LARS persist or worsen over time despite conservative measures, second-line interventions such as transanal irrigation or pelvic floor rehabilitation, can be initiated. A small proportion of patients will ultimately require an intervention such as sacral neuromodulation or permanent colostomy for refractory, major LARS symptoms.

Identifiants

pubmed: 34863592
pii: S0960-7404(21)00180-8
doi: 10.1016/j.suronc.2021.101691
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101691

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Richard Garfinkle (R)

Division of Colon and Rectal Surgery, Jewish General Hospital, Montreal, QC, Canada.

Marylise Boutros (M)

Division of Colon and Rectal Surgery, Jewish General Hospital, Montreal, QC, Canada. Electronic address: mboutros@jgh.mcgill.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH